rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Amy Bachrodt

Chief Financial Officer

Company insider

Files Form 4 as: Chief Financial Officer, Lycia Therapeutics; SVP, Finance, Maze Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
69
Buys
0
Sells
7
Bought
$0
Sold
$2.5M
Companies
2
Companies where not an officer
0
First trade
22 Sep 2025
Last trade
11 Aug 2026
Last filed
26 Oct 2026

Companies traded

Where they are an officer
LYCA Lycia TherapeuticsOfficer, 10% owner · Biotechnology · last 11 Aug 20260 buys · 0 sells
MAZE Maze TherapeuticsOfficer · Biotechnology · last 1 Apr 20260 buys · 7 sells

Activity over time

1 Dec 2025 – 1 Oct 2026
30Dec 25Mar 26May 26Aug 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
11 Aug 2026filed 26 Oct 2026LYCA Lycia Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—399,746 at $0.00filing
1 Apr 2026filed 2 Apr 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Code M$26K2,500 at $10.42filing
1 Apr 2026filed 2 Apr 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Sold$65K2,200 at $29.32filing
1 Apr 2026filed 2 Apr 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Sold$9,101300 at $30.34filing
1 Apr 2026filed 2 Apr 2026MAZE Maze Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—2,500 at $0.00filing
1 Apr 2026filed 2 Apr 2026MAZE Maze Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—2,500 at $0.00filing
1 Apr 2026filed 2 Apr 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Code M$26K2,500 at $10.42filing
1 Apr 2026filed 2 Apr 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Sold$65K2,200 at $29.32filing
1 Apr 2026filed 2 Apr 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Sold$9,102300 at $30.34filing
2 Mar 2026filed 3 Mar 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Code M$52K5,000 at $10.42filing
2 Mar 2026filed 3 Mar 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Sold$58K1,300 at $44.44filing
2 Mar 2026filed 3 Mar 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Sold$168K3,700 at $45.47filing
2 Mar 2026filed 3 Mar 2026MAZE Maze Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—5,000 at $0.00filing
2 Mar 2026filed 3 Mar 2026MAZE Maze Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—32,000 at $0.00filing
2 Mar 2026filed 3 Mar 2026MAZE Maze Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—16,000 at $0.00filing
2 Mar 2026filed 3 Mar 2026MAZE Maze Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code M—5,000 at $0.00filing
2 Mar 2026filed 3 Mar 2026MAZE Maze Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—32,000 at $0.00filing
2 Mar 2026filed 3 Mar 2026MAZE Maze Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—16,000 at $0.00filing
2 Mar 2026filed 3 Mar 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Code M$52K5,000 at $10.42filing
2 Mar 2026filed 3 Mar 2026MAZE Maze TherapeuticsBiotechnologySEC FORM 4 Sold$58K1,300 at $44.44filing

Sectors

Health Care7

Buys in green, sells in red, by the company’s sector.

Related people

Venrock Healthcare Capital Partners III, L.P.10% owner · 10% owner at Lycia Therapeutics, filing Form 4 there in the last year
William J.L. RieflinDirector · Director at Lycia Therapeutics, filing Form 4 there in the last year
Laurent FischerDirector · Director at Lycia Therapeutics, filing Form 4 there in the last year
Jane HendersonDirector · Director at Lycia Therapeutics, filing Form 4 there in the last year
Aetna Wun TrombleyPresident and CEO · President and CEO at Lycia Therapeutics, filing Form 4 there in the last year
Harold BernsteinPresident, R&D & CMO · Also traded MAZE in the last 90 days
Jason Coloma VChief Executive Officer · Also traded MAZE in the last 90 days
Atul DandekarCsbo · Also traded MAZE in the last 90 days